Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial
May 31, 2026
,
Atkins, M. et al.
ASCO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results.
SITC
Society for Immunotherapy of Cancer (SITC)
June 1, 2022
,
El-Khoueiry, et al.
No items found.
Balstilimab (PD-1 inhibitor)
RaPiDS (GOG-3028): A Randomized Phase II Study of Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer.
Other Articles & Publications
SGO 2021 Virtual Annual Meetings on Women's Cancer Abstracts
June 1, 2022
,
O'Malley, et al.
No items found.
Botensilimab (Fc-enhanced anti-CTLA-4)
Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors.
AACR
American Association for Cancer Research (AACR)
June 1, 2022
,
Tanne, et al.
No items found.